Get started
Author

Sylwia Marshall

Observed name: S. Marshall
ORCID: 0000-0001-6596-2786
Observed ORCID: 0000-0001-6596-2786
OpenAlex ID: A5064885286
FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models
2020 · Matthew A. Lakins, Alexander Koers, et al. · Clinical Cancer Research · 66
A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance
2022 · Timothy A. Yap, Patricia M. LoRusso, et al. · Clinical Cancer Research · 56
PDF
Phase 1 study of bispecific HER2 antibody-drug conjugate MEDI4276 in patients with advanced HER2-positive breast or gastric cancer
2018 · M. Pegram, E. Hamilton, et al. · Annals of Oncology · 16
AMP-224, a Fusion Protein that Targets PD-1
2013 · F. Smothers, A. Hoos, et al. · Annals of Oncology · 14
Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody: A phase 1, open-label study in advanced malignancies
2016 · O. Hamid, L.Q. Chow, et al. · Annals of Oncology · 12
PDF
91P Phase I dose escalation of IMC-C103C, a CD3×MAGE-A4 T-cell receptor (TCR) bispecific protein
2021 · D. Davar, R.F. Sweis, et al. · Annals of Oncology · 7
1033TiP A first-in-human phase I study of FS120, an OX40/CD137 tetravalent bispecific antibody, in patients with advanced malignancies
2021 · K. Papadopoulos, T.A. Yap, et al. · Annals of Oncology · 4
PDF
Translational endpoints in patients with metastatic microsatellite-stable colorectal cancer (MSS-CRC) treated with durvalumab plus monalizumab (anti-NKG2A)
2018 · J.R. Diamond, N. Standifer, et al. · Annals of Oncology · 4
Abstract 4547: Clustering CD137 via cell-expressed PD-L1 crosslinking avoided Fc-mediated agonism and resulted in safe and potent conditional lymphocyte activation
2020 · Matthew A. Lakins, Alexander Koers, et al. · Cancer Research · 1
Abstract 1540: FS222 mAb2, a bispecific conditional agonist antibody targeting CD137 and PD-L1, induces potent lymphocyte activation and has a favorable safety profile
2019 · Matthew A. Lakins, Alexander Koers, et al. · Immunology · 1
Abstract 1540: FS222 mAb2, a bispecific conditional agonist antibody targeting CD137 and PD-L1, induces potent lymphocyte activation and has a favorable safety profile
2019 · Matthew A. Lakins, Alexander Koers, et al. · Cancer Research · 1
A Phase 1 first-in-human study of MEDI0680, an anti-PD-1 monoclonal antibody (mAb) in adult patients (pts) with advanced tumors
2016 · A. Naing, S. Goel, et al. · Annals of Oncology · 1
PDF
1057 LGTX-101: A novel, highly selective and potent machine learning-derived Nectin-4 x CD3 T-cell engager in development for the treatment of solid tumours
2026 · Sylwia Marshall, Nathan Breeds, et al. · Journal for ImmunoTherapy of Cancer
PDF
Abstract 1626: A novel machine-learning derived nectin-4 x CD3 bispecific T-cell engager, LGTX-101, demonstrates high degrees of tumor selectivity and potently induces tumor regression in vivo
2026 · Lucrecia Alberdi, Sabrina Bouhafs, et al. · Cancer Research
Supplementary Tables S1-S3 from A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance
2025 · Timothy A. Yap, Patricia M. LoRusso, et al.
Supplementary Figures S1-S5 from A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance
2025 · Timothy A. Yap, Patricia M. LoRusso, et al.
PDF
Supplementary Information S1 from A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance
2025 · Timothy A. Yap, Patricia M. LoRusso, et al.
668 FS222 is a CD137/PD-L1 tetravalent, bispecific antibody which elicits robust pharmacodynamic activity in advanced solid tumor patients in a FIH study
2024 · Daniel Jones, Neil Benson, et al. · Journal for ImmunoTherapy of Cancer
Data from A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance
2023 · Timothy A. Yap, Patricia M. LoRusso, et al.
Data from A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance
2023 · Timothy A. Yap, Patricia M. LoRusso, et al.
Supplementary Tables S1-S3 from A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance
2023 · Timothy A. Yap, Patricia M. LoRusso, et al.
Supplementary Information S1 from A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance
2023 · Timothy A. Yap, Patricia M. LoRusso, et al.
Supplementary Figures S1-S5 from A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance
2023 · Timothy A. Yap, Patricia M. LoRusso, et al.
Combined Supplementary Data from FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models
2023 · Matthew A. Lakins, Alexander Koers, et al.
Combined Supplementary Data from FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models
2023 · Matthew A. Lakins, Alexander Koers, et al.
Works count: 28
Citation count: 183
H-index: 6
I10-index: 5
Year
Topic
Type